Certainty of Evidence. by Haribalakrishna Balasubramanian (21865971)

“…Compared to co-located care, transfer for surgery did not increase the odds of risk-adjusted and crude mortality in neonates with congenital diaphragmatic hernia [adjusted odds ratio (aOR):0.86 (0.49 to 1.49), 5 studies, 8366 infants; crude OR:0.68 (0.51 to 0.91, i.e., decreased mortality), 22 studies, 12970 infants], critical congenital heart disease [aOR:0.79 (0.42 to 1.48), 3 studies, 13485 infants; OR:1.04 (0.66 to 1.64), 10 studies, 14447 infants], surgical necrotizing enterocolitis [aOR:0.99 (0.61 to 1.61), 4 studies, 5891 infants; OR:1.03 (0.64 to 1.65), 5 studies, 5915 infants], gastroschisis [aOR:1.07 (0.68 to 1.68), 2 studies, 5294 infants; OR:0.80 (0.48 to 1.35), 11 studies, 8708 infants], tracheo-oesophageal fistula [aOR:0.97 (0.39 to 2.39), 1 study, 937 infants; OR:0.62 (0.37 to 1.04), 4 studies, 4050 infants], congenital or perinatal intestinal conditions [OR:2.69 (0.26 to 28.34), 4 studies, 1799 infants]. …”

Characteristics of included studies. by Haribalakrishna Balasubramanian (21865971)

“…Compared to co-located care, transfer for surgery did not increase the odds of risk-adjusted and crude mortality in neonates with congenital diaphragmatic hernia [adjusted odds ratio (aOR):0.86 (0.49 to 1.49), 5 studies, 8366 infants; crude OR:0.68 (0.51 to 0.91, i.e., decreased mortality), 22 studies, 12970 infants], critical congenital heart disease [aOR:0.79 (0.42 to 1.48), 3 studies, 13485 infants; OR:1.04 (0.66 to 1.64), 10 studies, 14447 infants], surgical necrotizing enterocolitis [aOR:0.99 (0.61 to 1.61), 4 studies, 5891 infants; OR:1.03 (0.64 to 1.65), 5 studies, 5915 infants], gastroschisis [aOR:1.07 (0.68 to 1.68), 2 studies, 5294 infants; OR:0.80 (0.48 to 1.35), 11 studies, 8708 infants], tracheo-oesophageal fistula [aOR:0.97 (0.39 to 2.39), 1 study, 937 infants; OR:0.62 (0.37 to 1.04), 4 studies, 4050 infants], congenital or perinatal intestinal conditions [OR:2.69 (0.26 to 28.34), 4 studies, 1799 infants]. …”

Risk of bias assessment. by Haribalakrishna Balasubramanian (21865971)

“…Compared to co-located care, transfer for surgery did not increase the odds of risk-adjusted and crude mortality in neonates with congenital diaphragmatic hernia [adjusted odds ratio (aOR):0.86 (0.49 to 1.49), 5 studies, 8366 infants; crude OR:0.68 (0.51 to 0.91, i.e., decreased mortality), 22 studies, 12970 infants], critical congenital heart disease [aOR:0.79 (0.42 to 1.48), 3 studies, 13485 infants; OR:1.04 (0.66 to 1.64), 10 studies, 14447 infants], surgical necrotizing enterocolitis [aOR:0.99 (0.61 to 1.61), 4 studies, 5891 infants; OR:1.03 (0.64 to 1.65), 5 studies, 5915 infants], gastroschisis [aOR:1.07 (0.68 to 1.68), 2 studies, 5294 infants; OR:0.80 (0.48 to 1.35), 11 studies, 8708 infants], tracheo-oesophageal fistula [aOR:0.97 (0.39 to 2.39), 1 study, 937 infants; OR:0.62 (0.37 to 1.04), 4 studies, 4050 infants], congenital or perinatal intestinal conditions [OR:2.69 (0.26 to 28.34), 4 studies, 1799 infants]. …”

Bidirectional control of absence seizures due to the competition between the SNr-TRN and SNr-SRN pathways. by Mingming Chen (535268)

“…<p>A, B: The state analysis (A) and frequency analysis (B) in the (<i>K</i>, <i>v</i>_{<i>p</i>₁<i>ζ</i>}) panel. …”

Image3_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.jpg by Emily M. J. Fennell (6654536)

DataSheet2_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.xlsx by Emily M. J. Fennell (6654536)

DataSheet6_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.xlsx by Emily M. J. Fennell (6654536)

Image4_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.JPEG by Emily M. J. Fennell (6654536)

Image7_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.JPEG by Emily M. J. Fennell (6654536)

DataSheet4_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.xlsx by Emily M. J. Fennell (6654536)

DataSheet3_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.xlsx by Emily M. J. Fennell (6654536)

DataSheet7_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.xlsx by Emily M. J. Fennell (6654536)

Image2_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.JPEG by Emily M. J. Fennell (6654536)

Image6_Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer.JPEG by Emily M. J. Fennell (6654536)

MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma by Morgan R. Davidson (171794)

“…MiR-218, encoded on 4p15.31 and 5q35.1 within two host genes (<em>SLIT2</em> and <em>SLIT3</em>), in a region of copy number loss, was selected as a priority candidate for follow-up as it is reported as underexpressed in lung cancer. …”

Trial design. by Llum Páez (22553360)

“…In summary, the contributions of Neoleish, a vaccine with a very high safety profile, to canine leishmaniasis prevention are: i) The odds-ratio for detectable parasites in blood is 3.5 for vaccinated dogs compared to non-vaccinated dogs; if detected, ~86% lower parasitemia levels are expected; ii) A vaccinated dog has a 2-fold lower risk of developing active infection compared to a non-vaccinated dog; in case positive, the parasite load in bone marrow is expected to be ~96% lower; iii) A 3-fold lower risk (~72.7%) of developing clinical disease is expected in a vaccinated compared to a non-vaccinated dog.…”

Schedule of the trial. by Llum Páez (22553360)

“…In summary, the contributions of Neoleish, a vaccine with a very high safety profile, to canine leishmaniasis prevention are: i) The odds-ratio for detectable parasites in blood is 3.5 for vaccinated dogs compared to non-vaccinated dogs; if detected, ~86% lower parasitemia levels are expected; ii) A vaccinated dog has a 2-fold lower risk of developing active infection compared to a non-vaccinated dog; in case positive, the parasite load in bone marrow is expected to be ~96% lower; iii) A 3-fold lower risk (~72.7%) of developing clinical disease is expected in a vaccinated compared to a non-vaccinated dog.…”

Clinical symptoms scoring system. by Llum Páez (22553360)

“…In summary, the contributions of Neoleish, a vaccine with a very high safety profile, to canine leishmaniasis prevention are: i) The odds-ratio for detectable parasites in blood is 3.5 for vaccinated dogs compared to non-vaccinated dogs; if detected, ~86% lower parasitemia levels are expected; ii) A vaccinated dog has a 2-fold lower risk of developing active infection compared to a non-vaccinated dog; in case positive, the parasite load in bone marrow is expected to be ~96% lower; iii) A 3-fold lower risk (~72.7%) of developing clinical disease is expected in a vaccinated compared to a non-vaccinated dog.…”

The effects of Mycobacterium tuberculosis on T cell responsiveness in granulomas by Jess Millar (620726)

“…<div>Background:</div><div>The pathologic hallmark of infection with <i>Mycobacterium tuberculosis</i> (Mtb) are granulomas, collections of host immune cells (e.g. macrophages and T cells) that organize in an attempt to contain and eliminate the infection. …”

Transfection of C/EBPα-saRNA inhibits metastasis by targeting EGFR/β-catenin signaling pathway. by Hongbo Huan (554599)

“…(C) Reduced gene expression of c-Myc, Axin2, CCDN1, and Lgr5 in C/EBPα-saRNA transfected HepG2 cells compared with scramble-saRNA transfected as the control. …”